Evaluating the Safety and Effectiveness of 5G Cloud Follow-up for Cardiovascular Implantable Electronic Devices

Launched by THE THIRD PEOPLE'S HOSPITAL OF CHENGDU · Oct 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to monitor and manage patients who have received cardiovascular implantable electronic devices (CIEDs), such as pacemakers and defibrillators. The goal is to see if using 5G technology for remote follow-up visits is as safe and effective as traditional in-person visits. Participants will continue to have regular check-ups at the clinic but will also use 5G cloud follow-up during these visits to ensure their devices are working properly and to make any necessary adjustments.

To be eligible for this trial, participants must be at least 18 years old and have not yet had their first follow-up appointment after getting a CIED. They will need to be willing to participate and sign a consent form. Unfortunately, those with a life expectancy of less than a year or who have certain mental health issues may not qualify. If you decide to participate, you can expect a mix of regular visits and advanced technology to help monitor your heart device, all while receiving care from a team of medical professionals.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years, gender unspecified;
• • 2. Patients who have not undergone their first clinic follow-up after the implantation of cardiovascular implantable electronic devices (CIED); Note: In this study, CIED includes pacemakers, implantable cardioverter defibrillators (ICD), cardiac resynchronization therapy pacemakers (CRT-P) and defibrillators (CRT-D), excluding implantable cardiac event recorders (ICM) and implantable cardiovascular monitors.
• • 3. Willing to participate in this clinical study and have signed the informed consent form in writing.
• Exclusion Criteria:
• * Exclusion Criteria:
• If meeting any of the following, the individual cannot be included:
• • 1. Life expectancy \< 1 year.
• • 2. Inability to cooperate with treatment or follow-up, such as having mental illness.
• • 3. Participated in other clinical studies within 30 days before enrollment. Other situations that the researcher deems unsuitable for inclusion.